UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 10, 2006
(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)			
DELAWARE	1-11353	13-3757370	
(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)	
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA	27215	336-229-1127	
(Address of principal executive offices)	(Zip Code)	(Registrant's telephone number including area	code)
Check the appropriate box below if the Form 8-K filing is intended collowing provisions: Written communications pursuant to Rule 425 under the Secur Soliciting material pursuant to Rule 14a-12 under the Exchang Pre-commencement communications pursuant to Rule 14d-2(I) Pre-commencement communications pursuant to Rule 13e-4(I)	rities Act (17 CFR 230. e Act (17 CFR 240.14a b) under the Exchange	425) a-12) Act (17 CFR 240.14d-2(b))	iny of the
TEM 7.01. Regulation FD Disclosure			
On February 10, 2006 Laboratory Corporation of America [®] Holdi President, Corporate Affairs, and William (Brad) Hayes, Executiv Global Healthcare Services Conference in New York, NY. LabCor Time).	e Vice President and C	Chief Financial Officer, are scheduled to speak a	at the UBS
Exhibits			
99.1 Press Release dated February 10, 2006			

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>Laboratory Corporation of America Holdings</u> (Registrant)

Date: February 15, 2006 By: /s/Bradford T. Smith

Bradford T. Smith, Executive Vice President and Secretary

Laboratory Corporation of America® Holdings 430 South Spring Street Burlington, NC 27215 Telephone:(336) 584-5171

FOR IMMEDIATE RELEASE

Investor Contact: Scott Fleming - 336-436-4879 Media Contact: Pam Sherry - 336-436-4855 Shareholder Direct: (800)LAB-0401 Company Information: www.LabCorp.com

LABCORP TO PRESENT AT THE UBS GLOBAL HEALTHCARE SERVICES CONFERENCE

Burlington, NC, February 10, 2006 — Laboratory Corporation of America[®] Holdings (LabCorp[®]) (NYSE: LH) today announced that Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the UBS Global Healthcare Services Conference in New York, NY. LabCorp's presentation is planned for Monday, February 13, 2006 at 10:30 a.m. (Eastern Time).

A live audio webcast of the presentation will be available via the Company web site at www.labcorp.com. An archived replay of the audio webcast will be available through March 15, 2006.

About LabCorp

Laboratory Corporation of America® Holdings, an S&P 500 company with a BBB investment-grade credit rating, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of \$3.1 billion in 2004, approximately 24,000 employees nationwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; ViroMed Laboratories, Inc. based in Minneapolis, MN; The Center for Esoteric Testing in Burlington, NC; DIANON *Systems*, Inc. based in Stratford, CT, US LABS based in Irvine, CA, and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our growing organization, visit our web site at: www.LabCorp.com.

Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2004 and subsequent SEC filings, and will be available in the Company's Form 10-K for the year ended December 31, 2005, when filed.